This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients

CORAL GABLES, Fla., March 29, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that researchers at the University of Pennsylvania have commenced a 60 subject, double-blind, placebo-controlled, investigator-sponsored study to evaluate the use of CPP-109 (vigabatrin) for the treatment of patients addicted to both cocaine and alcohol.

The researchers hope that the results from their study of CPP-109 will support the conduct of a larger clinical trial that could support FDA approval of CPP-109 as a treatment for cocaine and alcohol co-dependency. Such results, if successful, would also expand upon the initial promising results reported by Brodie , et al. in November 2009 in the American Journal of Psychiatry, in which significantly increased abstinence from alcohol use in subjects taking vigabatrin was also reported.

This study will be conducted by a team of researchers led by Kyle M. Kampman, M.D., Associate Professor of Psychiatry through his affiliation with the University of Pennsylvania School of Medicine's Treatment Research Center. In this trial, 60 subjects will receive either CPP-109 or matching placebo, in addition to weekly counseling for eight weeks. The primary outcome measures are cocaine abstinence confirmed by twice weekly urine drug screens and alcohol abstinence measured by self-report. Recruitment is targeted to be completed in 12 months. The study is being conducted at the University of Pennsylvania Treatment Research Center.

Catalyst will provide CPP-109 and matching placebo, and financial support to conduct eye-safety examinations to facilitate the study. The National Institute on Drug Abuse (NIDA) is providing the majority of funding for the study as a part of the pilot study program included in a P50 center grant headed by Helen Pettinati, Ph.D., Research Professor of Psychiatry.

This study is part of pilot project program being conducted at the University of Pennsylvania, the goal of which is to rapidly screen medications for the treatment of comorbid cocaine and alcohol dependence in small clinical trials. The pilot project program seeks to utilize state of the art techniques to ensure excellent medication adherence and treatment retention so that reliable results can be obtained rapidly to inform future larger trials. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,568.53 -127.94 -0.73%
S&P 500 2,079.65 -12.01 -0.58%
NASDAQ 5,088.63 -48.8540 -0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs